Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: New insights into a disease continuum

Annals of the New York Academy of Sciences

Volumn 1310, Issue 1, 2014, Pages 84-88

  Irons, Richard D ^a,b,c   Kerzic, Patrick J ^c  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO   (United States)

^c Cinpathogen Inc   (United States)

Author keywords

AML; Benzene; Cytogenetics; MDS

Indexed keywords

BENZENE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TOXICITY; CYTOGENETICS; HUMAN; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; OCCUPATIONAL EXPOSURE; PATHOGENESIS; TUMOR MICROENVIRONMENT;

AML; BENZENE; CYTOGENETICS; MDS;

ANIMALS; BENZENE; CELL TRANSFORMATION, NEOPLASTIC; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; TOXICITY TESTS;

EID: 84896263386     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12336     Document Type: Article

References (43)

1. Santesson, C. 1897. Uber chronische vergiftung mit steinkohlenteerbenzin: vier todesfalle. Arch. Hyg. Berl. 31: 336-376.
2. Aksoy, M. et al. 1972. Details of blood changes in 32 patients with pancytopenia associated with long-term exposure to benzene. Br. J. Ind. Med. 29: 56-64.
3. Young, N.S. 1988. "Drugs and chemicals as agents of bone marrow failure." In Hematopoiesis: Long Term Effects of Chemotherapy and Radiation. N.G. Testa & R.P. Gale, Eds. Pg. 131. New York: Marcel Dekker, Inc.
4. Hunter, F. 1939. Chronic exposure to benzene (benzol) II: the clinical effects. J. Indust. Hyg. Toxicol. 21: 331-354.
5. Young, N.S. & B.P. Alter. 1994. Aplastic Anemia: Acquired and Inherited. Philadelphia: W.B. Saunders Co.
6. Gross, S. et al. 2010. A hospital-based case control study of aplastic anemia in Shanghai, China. Chem. Biol. Interact. 184: 165-173.
7. Rowley, J.D. et al. 1981. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 58: 759-767.
8. Le Beau, M.M. et al. 1986. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J. Clin. Oncol. 4: 325-345.
9. Smith, S.M. et al. 2003. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102: 43-52.
10. Aksoy, M. et al. 1971. Haematological effects of chronic benzene poisoning in 217 workers. Br. J. Ind. Med. 28: 296-302.
11. Infante, P.F. et al. 1977. Leukaemia in benzene workers. Lancet 2: 76-78.
12. Irons, R.D. & W.S. Stillman. 1996. The process of leukemogenesis. Environ. Health Perspect. 104: 1239-1246.
13. Smith, M.T. & L.P. Zhang. 1998. Biomarkers of leukemia risk: benzene as a model. Environ. Health Perspect. 106(Suppl. 4): 937-946.
14. Zhang, L. et al. 2002. The nature of chromosomal aberrations detected in humans exposed to benzene. Crit. Rev. Toxicol. 32: 1-42.
15. WHO. 2001. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press.
16. WHO. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press.
17. Hayes, R.B. et al. 1997. Benzene and the dose-related incidence of hematologic neoplasms in China. J. Natl. Cancer Inst. 89: 1065-1071.
18. Wong, O. et al. 2010. A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of environmental and occupational risk factors by subtypes of the WHO classification. Chem. Biol. Interact. 184: 112-128.
19. Schnatter, A.R. et al. 2012. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J. Natl. Cancer Inst. 104: 1724-1737.
20. Irons, R.D. et al. 2013. Acute myeloid leukemia following exposure to benzene more closely resembles de novo than therapy related-disease. Genes Chromosomes Cancer 52: 887-894.
21. Irons, R.D. et al. 2010. Integrating WHO 2001-2008 criteria for the diagnosis of myelodysplastic syndrome (MDS): a case-case analysis of benzene exposure. Chem. Biol. Interact. 184: 30-38.
22. Irons, R.D. et al. 2005. Chronic exposure to benzene results in a unique form of dysplasia. Leuk. Res. 29: 1371-1380.
23. Song, Y. et al. 2010. Immunosuppressive therapy of cyclosporin A for severe benzene-induced hameatopoietic disorders and a 6-month follow-up. Chem. Biol. Interact. 186: 96-102.
24. + T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br. J. Haematol. 145: 64-72.
25. Aggarwal, S. et al. 2011. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br. J. Haematol. 153: 568-581.
26. Schattenberg, D.G. et al. 1994. Peroxidase activity in murine and human hematopoietic progenitor cells. Potential relevance to benzene-induced toxicity. Mol. Pharmacol. 46: 346-351.
27. + normal human hematopoietic cells. Blood 82: 2069-2078.
28. +cells. Mol. Pharmacol. 79: 479-487.
29. Odobasic, D. et al. 2013. Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function. Blood 121: 4195-4204.
30. Bonnet, D. & J.E. Dick. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3: 730-737.
31. + lineage-negative fraction. Leukemia 12: 1782-1788.
32. Jordan, C.T. 2002. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 16: 559-562.
33. Warner, J.K. et al. 2004. Concepts of human leukemic development. Oncogene 23: 7164-7177.
34. Edwards, R.H. et al. 1999. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia. Am. J. Clin. Pathol. 112: 819-827.
35. Grimwade, D. et al. 2002. The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells. Cancer Res. 62: 4730-4735.
36. Grimwade, D. & T. Enver. 2004. Acute promyelocytic leukemia: where does it stem from? Leukemia 18: 375-384.
37. Puccetti, E. & M. Ruthardt. 2004. Acute promyelocytic leukemia: PML/RARa and the leukemic stem cell. Leukemia 18: 1169-1175.
38. Wilson, A. & A. Trumpp. 2006. Bone marrow hematopoietic stem cell niches. Nat. Rev. Immunol. 6: 93-106.
39. Wilson, A. et al. 2008. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homoestasis and repair. Cell 135: 1118-1129.
40. Pietras, E. et al. 2011. Cell cycle regulation in hematopoietic stem cells. J. Cell Biol. 195: 709-720.
41. Kirouac, D. et al. 2009. Cell-cell interaction networks regulate blood stem and progenitor cell fate. Mol. Syst. Biol. 5: 293-299.
42. Ames, B.N. et al. 1973. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. U. S. A. 70: 2281-2285.
43. Ames, B.N. et al. 1987. Ranking possible carcinogenic hazards. Science 236: 271-280.